| Attributes | Values |
|---|
| rdf:type
| |
| Description
| - Abstract This study analyzed the prognostic significance of sIL-2Ralfa levels in 100 prospectively enrolled patients with previously untreated follicular lymphoma. It showed that sIL-2Ralfa level ? 115 pmol/L at the time of treatment initiation correlates with the high FLIPI-2, bulky disease, advanced clinical stage, number of involved lymph nodes, bone marrow involvement and elevated beta-2 microglobulin (B2M) level. When testing all patients, sIL-2Ralfa ? 115 pmol/L was associated with significantly shorter progression-free (PFS; p{0.03, HR 2.04) but not overall (OS; p=0.06, HR 2.36) survival rates. Subanalysis of the CHOP+-rituximab patients showed higher predictive power for both PFS (HR 2.75, 95% CI 1.24-6.11, p=0.01,) and OS (HR 3.33, 95% CI 1.15-9.63, p=0.02,). In the whole population (n=100), only B2M proved a significant univariate predictor (p=0.007, HR = 2.8) of the PFS. When testing patients treated with CHOP+-rituximab, sIL-2Ralfa was found to be the best univariate predictor for PFS among all FLIPI-2 factors (HR = 2.68, p=0.015). Serum IL-2Ralfa levels may help to refine risk assessment in the modern immunotherapy era complementary to FLIPI-2 factors.
- Abstract This study analyzed the prognostic significance of sIL-2Ralfa levels in 100 prospectively enrolled patients with previously untreated follicular lymphoma. It showed that sIL-2Ralfa level ? 115 pmol/L at the time of treatment initiation correlates with the high FLIPI-2, bulky disease, advanced clinical stage, number of involved lymph nodes, bone marrow involvement and elevated beta-2 microglobulin (B2M) level. When testing all patients, sIL-2Ralfa ? 115 pmol/L was associated with significantly shorter progression-free (PFS; p{0.03, HR 2.04) but not overall (OS; p=0.06, HR 2.36) survival rates. Subanalysis of the CHOP+-rituximab patients showed higher predictive power for both PFS (HR 2.75, 95% CI 1.24-6.11, p=0.01,) and OS (HR 3.33, 95% CI 1.15-9.63, p=0.02,). In the whole population (n=100), only B2M proved a significant univariate predictor (p=0.007, HR = 2.8) of the PFS. When testing patients treated with CHOP+-rituximab, sIL-2Ralfa was found to be the best univariate predictor for PFS among all FLIPI-2 factors (HR = 2.68, p=0.015). Serum IL-2Ralfa levels may help to refine risk assessment in the modern immunotherapy era complementary to FLIPI-2 factors. (en)
|
| Title
| - Soluble interleukin-2 receptor level predicts survival in patients with follicular lymphoma treated with CHOP chemotherapy in the rituximab era
- Soluble interleukin-2 receptor level predicts survival in patients with follicular lymphoma treated with CHOP chemotherapy in the rituximab era (en)
|
| skos:prefLabel
| - Soluble interleukin-2 receptor level predicts survival in patients with follicular lymphoma treated with CHOP chemotherapy in the rituximab era
- Soluble interleukin-2 receptor level predicts survival in patients with follicular lymphoma treated with CHOP chemotherapy in the rituximab era (en)
|
| skos:notation
| - RIV/61989592:15110/14:33144645!RIV15-MSM-15110___
|
| http://linked.open...avai/riv/aktivita
| |
| http://linked.open...avai/riv/aktivity
| |
| http://linked.open...iv/cisloPeriodika
| |
| http://linked.open...vai/riv/dodaniDat
| |
| http://linked.open...aciTvurceVysledku
| |
| http://linked.open.../riv/druhVysledku
| |
| http://linked.open...iv/duvernostUdaju
| |
| http://linked.open...titaPredkladatele
| |
| http://linked.open...dnocenehoVysledku
| |
| http://linked.open...ai/riv/idVysledku
| - RIV/61989592:15110/14:33144645
|
| http://linked.open...riv/jazykVysledku
| |
| http://linked.open.../riv/klicovaSlova
| - CHOP; rituximab; interleukin; autologous transplantation; chemotherapy; follicular lymphoma (en)
|
| http://linked.open.../riv/klicoveSlovo
| |
| http://linked.open...odStatuVydavatele
| - GB - Spojené království Velké Británie a Severního Irska
|
| http://linked.open...ontrolniKodProRIV
| |
| http://linked.open...i/riv/nazevZdroje
| |
| http://linked.open...in/vavai/riv/obor
| |
| http://linked.open...ichTvurcuVysledku
| |
| http://linked.open...cetTvurcuVysledku
| |
| http://linked.open...UplatneniVysledku
| |
| http://linked.open...v/svazekPeriodika
| |
| http://linked.open...iv/tvurceVysledku
| - Faber, Edgar
- Indrák, Karel
- Jarošová, Marie
- Langová, Kateřina
- Raida, Luděk
- Procházka, Vít
- Papajík, Tomáš
- Prouzová, Zuzana
- Kapitáňová, Zuzana
|
| issn
| |
| number of pages
| |
| http://bibframe.org/vocab/doi
| - 10.3109/10428194.2013.850167
|
| http://localhost/t...ganizacniJednotka
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)